Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 3/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12414847 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2POLBNPSR1L3MBTL1PTPN1 | |
| SCHEMBL12414849 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2POLBNPSR1L3MBTL1PTPN1 | |
| SCHEMBL12414840 | 0.90 | SMN1; SMN2 (0.43) | SMN1; SMN2POLBNPSR1L3MBTL1PTPN1 | |
| SCHEMBL12413723 | 0.90 | SMN1; SMN2 (0.43) | SMN1; SMN2POLBNPSR1L3MBTL1PTPN1 | |
| SCHEMBL12414841 | 0.90 | SMN1; SMN2 (0.43) | SMN1; SMN2POLBNPSR1L3MBTL1PTPN1 | |
| SCHEMBL12413725 | 0.89 | POLB (0.51) | SMN1; SMN2POLBNPSR1L3MBTL1PTPN1 | |
| SCHEMBL12578181 | 0.84 | GNAI3 (0.47) | POLBGNAI3GNAO1GNAI1KDM1A | |
| SCHEMBL15490019 | 0.84 | DPP4 (0.51) | SMN1; SMN2POLBNPSR1L3MBTL1PTPN1 | |
| SCHEMBL30333643 | 0.84 | DPP4 (0.51) | SMN1; SMN2POLBNPSR1L3MBTL1PTPN1 | |
| SCHEMBL23986710 | 0.80 | DPP4 (0.51) | SMN1; SMN2POLBNPSR1L3MBTL1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293729-B2 | Compounds, pharmaceutical composition and methods relating thereto | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| EP-1651635-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005009989-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009989-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| US-20050020587-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020587-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4D | SMN1; SMN2 2414/4885POLB 903/4885NPSR1 1757/4885 |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | MC2R, REN, CYP11B2 | SMN1; SMN2 1994/4885POLB 2094/4885NPSR1 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.